Powering the genetic medicine revolution
Our novel, synthetic DNA vector, “doggybone” or dbDNA™, and its enzymatic production, enable us to make DNA at the speed, scale and purity necessary to support the rapid growth of genetic medicines.
DNA made using enzymes
We are disrupting the decades-old technology of DNA production, moving away from restrictive biological approaches to instead use a synthetic DNA vector.Our platform technology
Enzymatic manufacturing enables multi-gram GMP DNA production in weeks rather than months
Manufactured using benchtop equipment with a significantly smaller footprint than fermentation-based production
dbDNA™ technology is highly portable and amenable to technology transfer
dbDNA™ can encode long, complex, unstable sequences, eliminates bacterial sequences, and has a strong expression profile
Addressing a broad market
Our versatile dbDNA™ technology is being applied across the genetic medicine industry.
What can we do for you?
We offer a range of services to support development and commercialisation of the next generation of DNA products.
- Catalogue products
- Molecular biology
- Custom research grade
- Toxicology materials
- GMP dbDNA™ (critical starting materials)
- GMP dbDNA™ (drug substance)
- Commercial supply / on-site supply
- Analytical development
- Scale up development
- Regulatory support
Headquartered in Hampton
Take a tour of our stunning buildings and state-of-the-art dbDNA™ manufacturing facilities.View our facilities
Info sheet – dbDNA catalogue productsDownload
Info sheet – Enzymatic DNA for AAV productionDownload
Case Study – CPI – Scaling up a new process to create synthetic DNARead more
Regulatory Framework for Platform Technologies (TOPRA article)Read Article
Webinar – Resolving the challenges of plasmid DNA in mRNA manufacturingRead Article
01 March 2022
Touchlight and Versameb announce GMP manufacturing supply agreement
Versameb moves forward with its lead asset towards clinical development with an Innovative synthetic doggybone DNA technology which increases quality and yield of mRNA therapeutics production Hampton, UK, Basel, Switzerland...
08 February 2022
AskBio and Touchlight Restructure Joint Venture
Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzymatic DNA production, have announced...
22 November 2021
Touchlight Ranked Number Four Fastest Growing Technology Company in the UK in the 2021 Deloitte Technology Fast 50
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announced that it ranked number 4 in the 2021 Deloitte UK Technology Fast 50, a...
We'd like to hear from you
For more information on how our dbDNA™ technology could help advance your project, please contact us.Get in touch